Semaglutide
⥠Quick Description & Benefits
FDA-approved GLP-1 receptor agonist. Marketed as Ozempic (type 2 diabetes) and Wegovy/Wegovy HD (chronic weight management). Weekly subcutaneous injection.
Key Benefits:
- â Activates GLP-1 receptors to increase satiety and reduce hunger
- â Clinically proven ~15% average weight loss on Wegovy (2.4 mg weekly) over 68 weeks
- â Improves insulin secretion and lowers HbA1c (Ozempic reduces HbA1c ~1.5%)
- â Reduces major adverse cardiovascular events (MACE) in overweight patients with CVD
- â Shown to reduce liver fat in MASLD/MASH patients
đŦ Detailed Function & Research
Mechanism & Function
FDA-approved GLP-1 receptor agonist. Marketed as Ozempic (type 2 diabetes) and Wegovy/Wegovy HD (chronic weight management). Weekly subcutaneous injection. It operates by stimulating specific cellular receptors, activating downstream enzymatic pathways and physiological repair mechanisms without widespread systemic disturbance.
Research & Scientific Support
Extensive pre-clinical and translational models demonstrate consistent receptor affinity and regenerative signalling across controlled studies.
Protocol Notes:
- âĸ FDA-approved GLP-1 receptor agonist (Ozempic 2017 for T2D; Wegovy 2021 for obesity).
- âĸ Long ~5-day half-life allows once-weekly dosing.
- âĸ Does NOT stack with Tirzepatide or Retatrutide â all hit the same GLP-1 receptor; combining offers no benefit and raises GI risk.
- âĸ Grey-market lyophilized "semaglutide" sold by peptide sites is an unapproved copy â quality, purity, and endotoxin levels are not verified by FDA.
- âĸ Cost: ~$900-$1,400/month retail with commercial insurance when available; compounded versions from telehealth clinics $200-$400/month (legal grey area).
𧎠Dosing & Reconstitution Calculator
Calculate syringe units or suggest optimal reconstitution solution volume
Volume Guideline: Most subcutaneous injections should fall between 10 and 20 units for optimal comfort, though certain peptides may feel better at volumes up to 60 units. Increments start at 1.0ml in 0.5ml steps.
đ Research Papers & Clinical Studies
Peer-reviewed research and indexed publications for Semaglutide:
đ Dosing & Administration
Escalate monthly to reduce GI side effects: âĸ Weeks 1-4: 0.25 mg once weekly âĸ Weeks 5-8: 0.5 mg once weekly âĸ Weeks 9-12: 1.0 mg once weekly âĸ Weeks 13-16: 1.7 mg once weekly âĸ Week 17 onward: 2.4 mg once weekly (standard maintenance) âĸ Wegovy HD: 7.2 mg once weekly (recently FDA-approved higher dose) Rotate injection sites among abdomen, thigh, and upper arm. Same day each week.
âĸ Weeks 1-4: 0.25 mg weekly âĸ Weeks 5-8: 0.5 mg weekly âĸ Week 9 onward: 1.0 mg weekly (max 2.0 mg weekly for additional glycemic control)
đ Pairs Well With
â ī¸ Side Effects
- ! Nausea (most common, usually mild-to-moderate and transient)
- ! Diarrhea, vomiting, constipation, abdominal pain
- ! Injection site reactions
- ! Decreased appetite (intended therapeutic effect)
- ! Delayed gastric emptying (rare cases of gastroparesis)
- ! Rare: pancreatitis, gallbladder disease, bowel obstruction
- ! Contraindicated with history of medullary thyroid carcinoma or MEN2